Skip to main content
Horama authorized by French regulator to launch retinitis pigmentosa drug study
10/12/2017

A Phase I/II study of Horama's drug candidate HORA-PDE6B for the treatment of patients with retinitis pigmentosa was authorized by the French National Agency for Medicines and Health Products Safety. The study will evaluate the safety and efficacy of the drug in patients with retinitis pigmentosa brought by biallelic mutations in the PDE6B gene.

Full Story: